Moderna's stock surge (177%) in August, driven by its Merck melanoma vaccine's Phase III success, signals a pivot beyond COVID. Watch for 2024 approval projections and CEO Bancel's "more than COVID" strategy to redefine Moderna as a high-margin oncology player.